Yingshan Han

List of Publications by Year
in descending order

13	391	840585 11	1125617 13
papers	citations	h-index	g-index

14	14	14	798
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Antimalarial drugs and their metabolites are potent Zika virus inhibitors. Journal of Medical Virology, 2019, 91, 1182-1190.	2.5	36
2	The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors. Journal of Infectious Diseases, 2018, 218, 698-706.	1.9	40
3	The antimalarial drug amodiaquine possesses antiâ€ZIKA virus activities. Journal of Medical Virology, 2018, 90, 796-802.	2.5	43
4	Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update. Expert Opinion on Investigational Drugs, 2018, 27, 951-962.	1.9	20
5	Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw514.	1.3	55
6	JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1. Journal of Virology, 2017, 91, .	1.5	11
7	The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration. MBio, 2017, 8, .	1.8	14
8	Investigational HIV integrase inhibitors in phase I and phase II clinical trials. Expert Opinion on Investigational Drugs, 2017, 26, 1207-1213.	1.9	16
9	Evaluation of Sofosbuvir (Î²-D-2â€²-deoxy-2â€²-Î±-fluoro-2â€²-Î²-C-methyluridine) as an inhibitor of Dengue virus replication #. Scientific Reports, 2017, 7, 6345.	1.6	58
10	Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase. Antimicrobial Agents and Chemotherapy, 2016, 60, 600-608.	1.4	33
11	The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound. Journal of the International AIDS Society, 2014, 17, 19518.	1.2	10
12	HIV-1 Group O Integrase Displays Lower Enzymatic Efficiency and Higher Susceptibility to Raltegravir than HIV-1 Group M Subtype B Integrase. Antimicrobial Agents and Chemotherapy, 2014, 58, 7141-7150.	1.4	8
13	Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. Journal of Antimicrobial Chemotherapy, 2014, 69, 2733-2740.	1.3	47